Skip to main content
Second Nordic Conference on Personalized Medicine

Scientific programme

8:00-9:30Arrival and registration
9:30-9:45Welcome and opening remarks
9:45-10:30Keynote lecture:
Ann K. Daly: Pharmacogenetics of drug-induced liver injury

Chair: Aleksi Tornio
11:00-12:30Plenary session 1:
Personalised medicine - Viewpoints from different stakeholders
Romaldas Maciulaitis: Biomarkers for R&D vs personalised medicine - Regulatory experience
Kimmo Porkka: Personalized cancer medicine: opportunities and challenges
Outi Vaarala: Personalised Medicine in Oncology Drug Discovery - What have we learned?

Chairs: Romaldas Maciulaitis, Miia Turpeinen
13:30-15:00Plenary session 2:
Clinical implementation of personalised medicine
Henk-Jan Guchelaar: Results from the U-PGx project
Julia Stingl: Personalised medicine in depression - patient profiling for the prediction of therapy outcome in a global perspective
From abstract:
Katriina Tarkiainen: Frequencies of clinically actionable genotypes in the Finnish population analyzed with a novel clinical massive parallel sequencing-based pharmacogenetics panel

Chairs: Espen Molden, Aleksi Tornio
15:00-16:00Coffee & Poster session
16:00-16:55Plenary session 3:
Drug-drug interactions
Jingjing Yu: Drug-drug interactions in the new FDA therapy approvals: mechanism and clinical significance
From abstract:
Ditte B. Iversen: Dicloxacillin decreases the concentration of dabigatran in healthy adults and induces P-gp in 3D spheroids of primary human hepatocytes

Chairs: Janne Backman
18:30-20:00Welcome reception (City of Turku)
8:30-10:00Plenary session 4:
Pharmacokinetic modelling and TDM for tomorrow
Amin Rostami-Hodjegan: PBPK Applications in Personalised Medicine and Combining It with Real-World Evidence
Erik Eliasson: Precision medicine and individual dosage of antimicrobial agents in the critically ill
From abstract:
Erik S. Dietrichs: Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in the elderly – a study based on a cohort of 19 742 patients

Chairs: Marja-Liisa Dahl, Anne Filppula
10:30-12:15Panel discussion:
Liquid biopsy in ADME
Amin Rostami-Hodjegan: Why do you need to know more about Liquid Biopsy? And why this needs to be ASAP
Andrew Rowland: Opportunities and challenges in understanding extracellular vesicles as a liquid biopsy to support precision medicine
Magnus Ingelman-Sundberg: Mechanisms of post translational regulation of hepatic cytochromes P450; Clinical implications

Chairs: Stefan Oswald, Janne Backman
13:15-14:45Plenary session 5:
Technological advances in the field of personalised medicine
Niklas Sandler Topelius: 3D printed drugs in personalized medicine
Stefan Oswald:Targeted LC-MS/MS analysis of protein abundancies in ADME research
From abstract:
Jouni Rantanen: Application of a multianalyte proteomic assay to document risk of future cardiovascular events in patients with type 2 diabetes

Chairs: Anne Filppula, Eriika Savontaus
14:45-15:45Coffee & Poster session
15:45-16:30Keynote lecture:
Munir Pirmohamed: Personalised medicine, current status and future perspectives

Chair: Mikko Niemi
18:30-21:00Conference dinner
(Restaurant Göran)
8:30-10:00Plenary session 6:
Joint ESPT session on clinical pharmacogenetics
Matthias Schwab: Pharmacogenetics and precision medicine in oncology
Ron van Schaik: Pharmacogenetics in clinical practice
From abstract:
Nina Wittwer: Utilization of drugs with pharmacogenetic dosing recommendations in children in Switzerland: a descriptive study using Swiss claims data

Chairs: Ann K. Daly, Mikko Niemi
10:30-12:00Plenary session 7:
Emerging treatment modalities in personalised medicine
Matthias B. Wittwer: Assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics
Joel Nordin: Extracellular Vesicles for Biomedical Applications
From abstract:
Nhu Ngoc Le: Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation

Chairs: Tore Stage, Ullamari Pesonen
12:00-12:15Closing remarks and awards
12:15-13:15Lunch (grab-and-go)

Programme is subject to changes.